⭐️ Top Level Player

The best offensive midfielder in #JPL 🇧🇪

🇨🇭 Cameron Puertas. #USGANT

☀️

💛💙
#USGANT

First ESMO - Eur. Oncology Virtual Journal Club on May 22 at 630pm (CEST) - pencil down your agendas! Important data to be discussed by experts George Pentheroudakis FabriceAndre Solange Peters Andres Cervantes
esmo.org/about-esmo-mee…

Another educational activity brought to you by ESMO - Eur. Oncology 👏

Very nice infographic on cancer vaccines on nature
OncoAlert

[THREAD] Je vais essayer de vous répondre de manière synthétique, Madame la Ministre, bien qu'il y ait des choses à dire.
↩️

Proud to present our post-mortem tissue donation program #UPTIDER dedicated to advance research on metastatic breast cancer! rdcu.be/dFCor Tatjana Geukens Maxim De Schepper KarenVanBaelen Fendt Lab @DiLa_lab Kevin Punie Hans Wildiers #FRichard #GFloris #bcsm OncoAlert

Out in ESMO Open the intracranial activity of T-DXd vs T-DM1 in the DESTINY-Breast03 phase 3 trial. Among patients with active brain mets, IC-ORR was 65.7% with T-DXd vs 34.3% with T-DM1. Accompanied by a podcast 🎙️ & an editorial by Dr Sarah Sammons Nancy Lin, MD. esmoopen.com/article/S2059-…

Such an important topic 👏 Becki Lee and all 💚

🚂 🎟️ already booked for #ESMOBreast24

Julien Uyttendaele Ecolo Julien, vous induisez le lecteur en erreur. Le texte déposé a été envoyé au Conseil d'Etat pour quelques mois au moins, et pas de notre fait. A quoi servirait une telle plénière ? A constater que le texte se trouve encore au Conseil d'Etat. Mais cela, de nouveau, vous le savez.

Phase I TROPION-PanTumor01 Study

✅Dato-DXd💊Shows promising efficacy and manageable safety in heavily pretreated🧬 HR+/HER2– #BreastCancer and #TNBC patients

➡️suggesting potential for advancement to phase III studies‼️

Aditya Bardia, MD
Ian E. Krop Dana-Farber…

✅Background and development in thoracic and breast malignancies
✅Biomarker research
✅Mechanisms of resistance
✅Future perspectives and collaborations

Solange Peters

A position statement from the ETOP IBCSG Partners Foundation Partners Foundation on current evidence and future directions for antibody-drug conjugates in lung and breast cancer in now available in Annals of Oncology
annalsofoncology.org/article/S0923-…

🔹The development of antibody-drug conugates has spurred & a number of agents are now SOC in different tumor types including in combinations
🔹The landscape of ongoing clinical trials will bring further changes to treatment algorithms
❓What are the challenges & what to expect?

La tribune Est du parc Duden 🎶
💛💙
#USGCLU

Blackthorne: Anderlecht losing, Bruges on the rise, don’t look dangerous, too many stupid mistakes, fucking flag stolen, still miss Teddy Teuma, if we lose the sea will rise, the sky will be on fire, Death will ride on horseback

Mariko: The Anjin says we have to win today

The long-awaited sun ☀️ is back in Antwerp for the first edition of BE-PRECISE, the Belgian Precision and Personalised Oncology Meeting, held thanks to a collaboration between academic institutions be-precise.be/plan-your-visit

#ESMOBreast24 : last hours to register at a preferential rate.
See what S. Delaloge, Evandro de Azambuja, MD, PhD, Erika Hamilton, MD and others are saying about this event. Register by 📅 17 April and save!

🔗ow.ly/3vPY50Rg6PY

💚

🙏
I do my best not to use war metaphors in the clinic